QTX3034 in Patients With KRAS G12D Mutation

Inclusion Criteria:

• Pathologically documented, locally advanced or metastatic malignancy with KRAS G12Dmutation identified through molecular testing (NGS- or PCR-based) with a ClinicalLaboratory Improvement Amendments-certified (or equivalent) diagnostic

• Part 1: - Advanced solid tumors with at least 1 prior systemic therapy

• Evaluable or Measurable disease per RECIST 1.1.

• Parts 2 and 3: Measurable disease per RECIST 1.1.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

• Adequate organ function

Exclusion Criteria:

• Prior treatment with a KRAS inhibitor

• Active brain metastases or carcinomatous meningitis

• History of other malignancy within 2 years

• Significant cardiovascular disease

• Disease or disorder that may pose a risk to patient's safety

Other protocol-defined Inclusion/Exclusion Criteria may apply